Chardan Capital Increases Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $25.00
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) had its price objective increased by equities researchers at Chardan Capital from $23.00 to $25.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s target price indicates a potential upside of 227.23% from […]
More Stories
TSS, Inc. (NASDAQ:TSSI) COO Karl Todd Marrott Sells 29,778 Shares
TSS, Inc. (NASDAQ:TSSI – Get Free Report) COO Karl Todd Marrott sold 29,778 shares of the stock in a transaction...
Insider Selling: CCC Intelligent Solutions Holdings Inc. (NYSE:CCCS) CAO Sells 9,916 Shares of Stock
CCC Intelligent Solutions Holdings Inc. (NYSE:CCCS – Get Free Report) CAO Rodney Christo sold 9,916 shares of CCC Intelligent Solutions...
Financial Comparison: Unity Biotechnology (NASDAQ:UBX) versus PainReform (NASDAQ:PRFX)
Unity Biotechnology (NASDAQ:UBX – Get Free Report) and PainReform (NASDAQ:PRFX – Get Free Report) are both small-cap medical companies, but...
Dell Technologies (NYSE:DELL) Updates FY 2025 Earnings Guidance
Dell Technologies (NYSE:DELL – Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The...
Western Asset Premier Bond Fund (NYSE:WEA) Raises Dividend to $0.07 Per Share
Western Asset Premier Bond Fund (NYSE:WEA – Get Free Report) announced a dividend on Monday, November 25th,NASDAQ Dividends reports. Shareholders...
Guess? (NYSE:GES) Issues Q4 2025 Earnings Guidance
Guess? (NYSE:GES – Get Free Report) updated its fourth quarter 2025 earnings guidance on Tuesday. The company provided earnings per...